Core Viewpoint - BellRing Brands, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices by its senior management [1]. Group 1: Recent Developments - On May 5, 2025, BellRing announced that several key retailers reduced their weeks of supply on hand, which is expected to negatively impact Q3 2025 growth. The company also stated it would expand promotions to counteract reductions in retailer trade inventory levels. Following this announcement, BellRing's share price fell by $13.96, or approximately 18%, from $77.34 to $63.38 [2]. - On August 4, 2025, BellRing reported disappointing quarterly consumption of Premier Protein RTD Shakes, which did not meet expectations due to previously announced retailer destocking. This led to a significant decline in share price by $17.46, or approximately 33%, from $53.64 to $36.18 [3].

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Soleno Therapeutics, Inc. regarding possible violations of federal securities laws or unlawful business practices [1] Group 1: Company Overview - Soleno Therapeutics, Inc. is under scrutiny following a report by Scorpion Capital that criticized its only product, Vykat XR, labeling it as overpriced and potentially unsafe for children [2] - The company's stock price experienced significant declines following negative reports and disclosures about Vykat XR, with a drop of approximately 7.41% on August 15, 2025, and a further decline of about 26.59% on November 5, 2025 [2][3] Group 2: Financial Impact - Following the Scorpion Capital report, Soleno's share price fell from $77.36 to $71.64, a decrease of $5.73 per share [2] - On November 4, 2025, Soleno disclosed a discontinuation rate of approximately 8% for Vykat XR due to adverse effects, which contributed to a further decline in share price from $63.85 to $46.87, a drop of $16.98 per share [3]

Group 1 - Anika Therapeutics, Inc. is under investigation by Kirby McInerney LLP for potential violations of federal securities laws or unlawful business practices by the company or its senior management [1] - On July 30, 2025, Anika announced topline results from its clinical trial of Hyalofast, which showed improvements in treated patients but did not meet pre-specified co-primary endpoints due to a higher dropout rate and missed visits during COVID [2] - Following the announcement, Anika's share price fell by $3.06, approximately 27.42%, closing at $8.10 per share on the same day [2] Group 2 - Investors who purchased or acquired Anika securities and have information regarding the investigation are encouraged to contact Kirby McInerney LLP for further discussion about their rights or interests [3] - Kirby McInerney LLP specializes in securities litigation and has achieved recoveries totaling billions of dollars for shareholders [4]

Core Viewpoint - Alexandria Real Estate Equities, Inc. is facing a federal securities class action lawsuit due to allegations of misleading information regarding its leasing spreads, development pipeline, and occupancy growth, particularly concerning its Long Island City property [3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Alexandria securities between January 27, 2025, and October 27, 2025, alleging that the company lacked reliable information about its life-science properties [3]. - It is claimed that Alexandria's optimistic reports about its development pipeline and occupancy rates were materially misleading, as the value and growth potential of its Long Island City property had been declining for years [3]. Group 2: Financial Performance - On October 27, 2025, Alexandria reported Q3 2025 financial results that did not meet analyst expectations, showing declining revenues and a 7% decrease in adjusted funds from operations [4]. - The financial report included a real estate impairment charge of $323.9 million, with $206 million attributed to the Long Island City property, leading to a significant drop in share price by approximately 19.17% from $77.87 to $62.94 [4].

Core Viewpoint - A class action lawsuit has been filed against Firefly Aerospace Inc. for alleged securities fraud during the period from August 4, 2025, to September 29, 2025, claiming misleading statements in their IPO documents and overstated operational capabilities [3]. Group 1: Lawsuit Details - The lawsuit alleges that Firefly's Offering Documents for its August 2025 IPO contained untrue statements and omitted necessary facts, failing to comply with regulatory standards [3]. - It is claimed that Firefly overstated the demand and growth prospects for its Spacecraft Solutions offerings and the operational readiness of its Alpha rocket program [3]. Group 2: Financial Performance - Firefly conducted its IPO on August 7, 2025, selling 19.296 million shares at $45.00 per share [4]. - In its first earnings report as a public company on September 22, 2025, Firefly reported a loss of $80.3 million, or $5.78 per share, compared to a loss of $58.7 million, or $4.60 per share, for the same quarter in 2024 [5]. - Revenue for the second quarter of 2025 was reported at $15.55 million, below analyst estimates of $17.25 million and down 26.2% year-over-year [5]. - The Spacecraft Solutions segment generated only $9.2 million in revenue, reflecting a 49% year-over-year decrease [5]. Group 3: Stock Price Impact - Following the earnings report, Firefly's share price dropped by $7.58, or approximately 15.3%, from $49.52 to $41.94 [5]. - After the disclosure of a failure in the Alpha Flight 7 rocket on September 29, 2025, shares fell by $7.64, or about 20.7%, from $36.96 to $29.32 [6].

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Lakeland Industries, Inc. regarding possible violations of federal securities laws or unlawful business practices [1]. Group 1: Financial Performance - Lakeland reported net sales of $47.6 million for Q3 2026, with adjusted EBITDA, excluding foreign exchange effects, at $200,000, representing a decrease of $4.5 million or 95% compared to the prior year [3]. - The company experienced a net loss of $16 million, equating to ($1.64) per basic and diluted share, in contrast to a net income of $100,000 or $0.01 per share in the same quarter of the previous year [3]. - Following the earnings report, Lakeland's share price fell by $5.85, or approximately 38.97%, from $15.01 on December 9, 2025, to close at $9.16 on December 10, 2025 [3]. Group 2: Management Commentary - CEO James Jenkins attributed the poor financial results partly to "delays in certification," indicating that the company anticipated certification to occur in March 2026 [3].

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Fermi Inc. regarding possible violations of federal securities laws or unlawful business practices [1]. Group 1: Company Overview - Fermi Inc. began trading on NASDAQ on October 1, 2025, at a price of $21.00 per share following its Initial Public Offering [3]. - The company faced a significant setback when its first tenant for the Project Matador AI campus terminated a $150 million Advance in Aid of Construction Agreement [3]. Group 2: Market Reaction - Following the announcement of the tenant's termination, Fermi's share price dropped by $5.16, which is approximately 33.8%, closing at $10.09 on December 12, 2025, down from $15.25 on December 11, 2025 [3].

Core Viewpoint - The lawsuit against Perrigo Company plc alleges that the company made materially false statements and failed to disclose significant issues regarding its infant formula business, leading to overstated financial results [3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Perrigo securities from February 27, 2023, to November 4, 2025, alleging misleading statements about the infant formula business [3]. - Specific allegations include underinvestment in maintenance and operational improvements, the need for substantial capital expenditures beyond stated estimates, and significant manufacturing deficiencies [3]. Group 2: Financial Impact - On November 5, 2025, Perrigo reported its third-quarter financial results and lowered its full-year guidance due to poor OTC consumption and issues with the infant formula business [4]. - Following this announcement, Perrigo's share price dropped by $5.09, approximately 25.2%, from $20.19 to $15.10 [4].

Core Viewpoint - Fiserv, Inc. is facing a securities fraud class action lawsuit due to misleading statements and omissions regarding its business initiatives during the specified class period [3][4]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of investors who purchased Fiserv securities from July 23, 2025, to October 29, 2025 [3]. - Allegations include that Fiserv made misleading statements about its initiatives and projects [3]. Impact on Stock Price - On October 29, 2025, Fiserv disclosed that its 2025 guidance was based on assumptions that were difficult to achieve, leading to a significant stock price drop of $55.57, or approximately 44%, from $126.17 to $70.60 [4]. Investor Actions - Investors who suffered losses on Fiserv investments have until January 5, 2026, to request lead plaintiff appointment [2]. - The law firm Kirby McInerney LLP is encouraging affected investors to contact them for discussions regarding their rights at no cost [1][4].

Core Viewpoint - Venu Holding Corporation is under investigation for potential violations of federal securities laws and unlawful business practices by its senior management [1]. Group 1: Company Overview - Venu conducted its initial public offering on November 27, 2024, offering 1.2 million shares at a price of $10.00 per share [3]. - The company reported third-quarter financial results on November 14, 2025, with revenue of $5.38 million, which is a 1.3% decline year-over-year and $2.05 million below consensus estimates [3]. Group 2: Market Reaction - Following the financial results announcement, Venu's share price dropped by $2.37, or approximately 21.45%, from $11.05 on November 14, 2025, to close at $8.68 on November 17, 2025 [3].